Norway backs downs over plan to exclude anticancer drugs from coverage

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f1707 (Published 14 March 2013)
Cite this as: BMJ 2013;346:f1707

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Anders Hansen
  1. 1Stockholm

After strong public reaction, Norway’s health minister, Jonas Gahr Støre, has reversed a decision to exclude the two anticancer drugs ipilimumab and abiraterone from the list of drugs covered by national insurance.

Ipilimumab is a human monoclonal antibody used against inoperable melanoma or in cases where the melanoma has spread. The drug has been shown to prolong the life of most patients by two to six …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL